Product
Adagrasib/Nivolumab
1 clinical trial
1 indication
Indication
Resectable Non-Small Cell Lung CancerClinical trial
Phase 2 Trial of Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)Status: Recruiting, Estimated PCD: 2025-11-01